• 1
    Gill J, May M, Lewden C et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 13871396.
  • 2
    Mocroft A, Reiss P, Gasiorowski J et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Jaids-J Acquir Immune Defic Syndr 2010; 55: 262270.
  • 3
    Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166: 16321641.
  • 4
    Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus – a 20-year prospective study. Jaids-J Acquir Immune Defic Syndr 2008; 47: 221225.
  • 5
    Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562569.
  • 6
    Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 8288.
  • 7
    EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245264.
  • 8
    Opravil M, Sasadeusz J, Cooper DA et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: 3649.
  • 9
    Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97100.
  • 10
    Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36: 10391046.
  • 11
    Mocroft A, Rockstroh J, Soriano V et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38: 10921097.
  • 12
    Rauch A, Egger M, Reichen J, Furrer H. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. Jaids-J Acquir Immune Defic Syndr 2005; 38: 238240.
  • 13
    Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 2229.
  • 14
    Grint D, Peters L, Reekie J et al. Stability of hepatitis C virus (HCV) RNA levels among interferon-na+»ve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med 2013; n/a.
  • 15
    Soriano V, Mocroft A, Rockstroh J et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 13371344.
  • 16
    Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835847.
  • 17
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289293.
  • 18
    Peters L, Mocroft A, Soriano V et al. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. Plos One 2013; 8: e64283.
  • 19
    Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids 2008; 22: 19791991.
  • 20
    Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518526.
  • 21
    Peters L, Rockstroh JK. Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes? Curr opin HIV AIDS 2010; 5: 517523.
  • 22
    Resino S, Bellon J, Asensio C et al. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis 2010; 10: 244.
  • 23
    Resino S, S+ínchez-Conde M, Berenguer J. Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr Opin Infect Dis 2012; 25: 564569.
  • 24
    Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010; 8: 972978.
  • 25
    Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56: 320325.
  • 26
    Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration. Antivir Ther 2012; 17: 15411550.
  • 27
    Carrat F. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (Chicago, Ill) 2004; 292: 28392848.
  • 28
    Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451459.
  • 29
    Laguno M. Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 2231.
  • 30
    Ingiliz P. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012; 32: 11941199.
  • 31
    Naggie S. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012; 142: 13241334.
  • 32
    Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120U178.
  • 33
    Rauch A, Martin M, Weber R et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV cohort study. Clin Infect Dis 2005; 41: 395402.
  • 34
    van de Laar TJ, van der Bij AK, Prins M et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230238.
  • 35
    Deterding K. Early versus delayed treatment of acute hepatitis C: final results of the randomized controlled German hep-net acute HCV-III study. J Hepatol 2012; 56: S21.
  • 36
    Gerlach JT. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 8088.